FIGURE 6.

MiR-29a promotes angiogenesis by activating AKT signaling. A, Western blot analysis of p-AKT in bEnd.3 cells with the indicated treatments, showing that pretreatment with LY294002 (LY) abrogates the stimulating role of miR-29a overexpression (29a M) on p-AKT expression. B, real-time PCR analysis of VEGF₁₆₄ expression in bEnd.3 cells with the indicated treatments, showing that pretreatment with LY294002 abrogates the stimulating role of miR-29a overexpression on VEGF₁₆₄ expression. C, treatment with LY294002 blocked the effect of miR-29a in promoting EC migration of bEnd.3 cells (left panel). The migrated distance of the wound edge was quantified (right panel). Scale bar = 100 μm. *, p < 0.05; **, p < 0.01. n = 6. D, treatment with LY294002 blocked the effect of miR-29a in promoting tube formation in Matrigel (left panel). The lengths of newly formed tubes were quantified (right panel). Scale bar = 0.5 mm. *, p < 0.05; **, p < 0.01. n = 3. E, LY294002 neutralized the stimulating role of miR-29a overexpression on CAM angiogenesis (left panel). The newly formed vessels were counted (right panel). Scale bar = 1 mm. *, p < 0.05; **, p < 0.01. n = 3. The red lines indicate the vessels around the filter paper.